Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.alpalabs.in | |
Market Cap | 201.97 Cr. | |
Enterprise Value(EV) | 203.53 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 8.55 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 11.23 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.22 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 70.26 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 1.37 | Calculated using Price: 95.99 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 2.10 Cr. | 21,040,600 Shares |
FaceValue | 10 | |
About Alpa Laboratories Ltd. | ||
Alpa Laboratories, incorporated in 1988, is engaged in the business of manufacturing pharmaceutical products. In 1967, the company started its journey as a partnership concern with Purushottam R Patel, M S Chawla and Pravin C Shah as the founding partners. Later on March 18, 1988 the company became a private limited company and a decade later it became a public limited enterprise. |
1 Day |
|
+1.05% |
1 Week |
|
+6.03% |
1 Month |
|
+9.05% |
3 Month |
|
-4.10% |
6 Month |
|
+32.23% |
1 Year |
|
+55.02% |
2 Year |
|
+12.57% |
5 Year |
|
+278.66% |
10 Year |
|
+924.60% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -1.6 | 7.61 | 2.68 | 2.92 | 1.03 | 1.86 | 6.97 | 12.29 | 9.82 | |
Return on Capital Employed (%) | -0.89 | 9.61 | 6.59 | 5.47 | 3.26 | 3.09 | 10.42 | 16.81 | 12.19 | |
Return on Assets (%) | -1.1 | 4.99 | 1.86 | 2.29 | 0.84 | 1.54 | 5.56 | 9.53 | 7.8 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 87 | 93 | 95 | 98 | 98 | 100 | 108 | 122 | 135 | 143 | |
Non Curr. Liab. | 0 | 1 | 0 | 0 | 0 | -1 | 0 | 5 | 3 | 2 | |
Curr. Liab. | 41 | 52 | 30 | 23 | 22 | 21 | 33 | 29 | 30 | 38 | |
Minority Int. | |||||||||||
Equity & Liab. | 128 | 146 | 125 | 121 | 121 | 120 | 140 | 155 | 167 | 184 | |
Non Curr. Assets | 16 | 27 | 20 | 23 | 27 | 25 | 19 | 17 | 18 | 16 | |
Curr. Assets | 113 | 119 | 105 | 98 | 94 | 95 | 121 | 138 | 149 | 168 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 128 | 146 | 125 | 121 | 121 | 120 | 140 | 155 | 167 | 184 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 57 | 54 | 63 | 63 | 78 | 86 | 98 | 112 | 93 | 114 | |
Other Income | 3 | 6 | 5 | 5 | 5 | 3 | 4 | 11 | 9 | 10 | |
Total Income | 61 | 59 | 69 | 68 | 83 | 89 | 102 | 123 | 102 | 125 | |
Total Expenditure | -55 | -47 | -56 | -59 | -77 | -83 | -90 | -102 | -85 | -100 | |
PBIDT | 6 | 12 | 12 | 9 | 6 | 6 | 12 | 21 | 17 | 24 | |
Interest | -2 | -1 | -2 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | |
Depreciation | -6 | -1 | -3 | -3 | -3 | -3 | -1 | -2 | -1 | -2 | |
Taxation | 1 | -3 | -3 | -2 | -2 | -1 | -4 | -5 | -3 | -4 | |
Exceptional Items | -1 | -2 | 0 | ||||||||
PAT | -1 | 7 | 3 | 3 | 1 | 2 | 7 | 14 | 13 | 18 | |
Minority Interest | |||||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | -1 | 7 | 3 | 3 | 1 | 2 | 7 | 14 | 13 | 18 | |
Adjusted EPS | -1 | 3 | 1 | 1 | 0 | 1 | 3 | 7 | 6 | 9 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 8 | -2 | -22 | 17 | -13 | -1 | 18 | -2 | 10 | 9 | |
Cash Fr. Inv. | -2 | 37 | -8 | -2 | -11 | -15 | -11 | 6 | -16 | 2 | |
Cash Fr. Finan. | 4 | 7 | -6 | -15 | 9 | -5 | -1 | 0 | 5 | -4 | |
Net Change | 10 | 42 | -36 | 0 | -15 | -20 | 5 | 4 | 0 | 7 | |
Cash & Cash Eqvt | 10 | 53 | 17 | 37 | 21 | 1 | 6 | 11 | 2 | 9 |
Thu, 04 Apr 2024
Trading Window-XBRL ALPA LABORATORIES LIMITED has informed the Exchange about Closure of Trading Window |
Mon, 01 Apr 2024
Trading Window Alpa Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
Mon, 18 Mar 2024
Clarification - Financial Results The Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Dec-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies The response of the Company is awaited. |
Wed, 24 Apr 2024 |
Making Higher Highs for 3 days |
Making Higher Highs for 2 Days |
High Increase in 1 Month |
High Increase in 6 Months |
High Increase in 1 Year |